A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-.kappa.B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I): ##STR00001## where X is S, O or N; Z is --T--COOR.sup.1 or --T--COR.sup.1; and T, R, R.sup.1, R.sup.a, R.sup.b, R.sup.c, R.sup.d, Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.